BridgeBio Pharma, Inc. (BBIO) Price Prediction 2026–2050

BridgeBio Pharma, Inc. is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases.

Its portfolio includes Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage for the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases.

It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd.

BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc. (BBIO) trades at $90.17 per share and has a market cap of $17.66B, ranking 644.

The current price sits near resistance at $90.17 with a 30-day range from $76.35 to $106.49, and the stock carries bullish technical momentum as reflected by a bullish sentiment reading. The forecast shows a long-term bullish trajectory, with the average price projected to rise from around $90.17 in 2026 to $237.17 by 2030 and further to $2,008.46 by 2050, with even higher potential maxima in each horizon.

The multi-year outlook features rising average prices and expanding upside, with ROI percentages growing from 47.1% in 2027 to 2,127.4% by 2050, and sentiment remaining bullish across the forecast years. The combination of a current price, notable market cap, and the forecast path suggests meaningful upside potential over the longer term while acknowledging the inherent uncertainty of forecasts.

The multi-year forecast shows clear bullish sentiment with substantial upside across the horizon.

For 2030, the forecast lists an average price of $237.17 with a potential low of $178.10 and a high of $339.66, and an expected ROI of 163%. By 2040, the average price is projected to be $810.83 with a max of $1,337.32 and a ROI of 799.2%, while 2050 shows an average of $2,008.46 and a max of $3,607.61, with a ROI of 2,127.4%.

This trajectory signals meaningful long-term upside, but it also carries the usual uncertainties of forecast models. These figures are estimates, not guarantees, and actual results may differ due to market conditions, clinical development outcomes, and regulatory or competitive factors.

Key intermediate years show continued bullish momentum, with 2027 averaging $132.63 and rising through 2029 to $211.23, followed by continued gains into the 2030s and beyond, all under a bullish sentiment framework.